• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Immuneering Corporation - Class A Common Stock (NQ:IMRX)

    4.279 -0.211 (-4.69%)
    Streaming Delayed Price Updated: 2:15 PM EDT, Jun 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Immuneering Corporation - Class A Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Present at the Leerink Global Healthcare Conference
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
    EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
    From FN Media Group LLC
    Via GlobeNewswire
    News headline image
    Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Announces Closing of $25 Million Private Placement
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Announces $25 Million Private Placement
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
    From Immuneering Corporation
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.